Inventor · disambiguated record
Ross Kenyon
Also filed as: KENYON ROSS
1 granted patent·12 pending applications·0 citations·filing 2021–2024
13Inventor score
Files withREGENERON PHARMA13
Top patents by PatentIndex Score
13 records- 0182US2025127992A1Devices and methods for precision dose deliveryREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0279US2024173485A1Devices and methods for precision dose deliveryREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0373US2022355040A1Devices and methods for precision dose deliveryREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 0470US2022126023A1Devices and methods for precision dose deliveryREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 0561US2024075204A1Auto-injector and related methods of useREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0659US2024382677A1Auto-injector and related methods of useREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0758US2022118177A1Auto-injector and related methods of useREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 0858US2022193343A1Auto-injector and related methods of useREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 0957US12226614B2Auto-injector and related methods of useREGENERON PHARMA·Filed 2021·Granted Feb 18, 2025·0 cites·20 claims
- 1046US2024152673A1Methods and systems for developing mixing protocolsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1142US2022318455A1System and methods for simulation of medical devicesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1240US2022047420A1Systems and methods for drug delivery to ocular tissueREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1339US2022309215A1Methods and systems for developing mixing protocolsREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ross Kenyon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →